SELECT data_key, data_value
FROM xf_data_registry
WHERE data_key IN ('options', 'languages', 'contentTypes', 'codeEventListeners', 'deferredRun', 'simpleCache', 'addOns', 'defaultStyleProperties', 'routeFiltersIn', 'routeFiltersOut', 'routesPublic', 'nodeTypes', 'bannedIps', 'discouragedIps', 'styles', 'displayStyles', 'userBanners', 'smilies', 'bbCode', 'threadPrefixes', 'userTitleLadder', 'reportCounts', 'moderationCounts', 'userModerationCounts', 'notices', 'userFieldsInfo')Run Time: 0.000479
| Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
|---|
| SIMPLE | xf_data_registry | range | PRIMARY | PRIMARY | 27 | | 26 | Using where |
SELECT data_key, data_value
FROM xf_data_registry
WHERE data_key IN ('brListenerClasses', 'brBriviumAddOns')Run Time: 0.000158
| Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
|---|
| SIMPLE | xf_data_registry | range | PRIMARY | PRIMARY | 27 | | 2 | Using where |
SELECT *
FROM xf_brivium_addon
ORDER BY addon_id
Run Time: 0.000167
| Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
|---|
| SIMPLE | xf_brivium_addon | index | | PRIMARY | 77 | | 1 | |
INSERT INTO xf_data_registry
(data_key, data_value)
VALUES
(?, ?)
ON DUPLICATE KEY UPDATE
data_value = VALUES(data_value)
Params: brBriviumAddOns, a:0:{}
Run Time: 0.000122
SELECT cache_value
FROM xf_permission_combination
WHERE permission_combination_id = ?
Params: 1
Run Time: 0.000150
| Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
|---|
| SIMPLE | xf_permission_combination | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SELECT thread.*
,
user.gender, user.avatar_date, user.gravatar,
NULL AS thread_read_date,
0 AS thread_reply_banned,
0 AS thread_is_watched,
'' AS draft_message, NULL AS draft_extra
FROM xf_thread AS thread
LEFT JOIN xf_user AS user ON
(user.user_id = thread.user_id)
WHERE thread.thread_id = ?
Params: 590716
Run Time: 0.000435
| Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
|---|
| SIMPLE | thread | const | PRIMARY | PRIMARY | 4 | const | 1 | |
| SIMPLE | user | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SELECT node.*, forum.*
,
permission.cache_value AS node_permission_cache,
NULL AS forum_read_date
FROM xf_forum AS forum
INNER JOIN xf_node AS node ON (node.node_id = forum.node_id)
LEFT JOIN xf_permission_cache_content AS permission
ON (permission.permission_combination_id = 1
AND permission.content_type = 'node'
AND permission.content_id = forum.node_id)
WHERE node.node_id = ?
Params: 25
Run Time: 0.000393
| Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
|---|
| SIMPLE | forum | const | PRIMARY | PRIMARY | 4 | const | 1 | |
| SIMPLE | node | const | PRIMARY | PRIMARY | 4 | const | 1 | |
| SIMPLE | permission | const | PRIMARY | PRIMARY | 35 | const,const,const | 1 | |
SELECT post.*
,
thread.*, thread.user_id AS thread_user_id, thread.username AS thread_username,
thread.post_date AS thread_post_date,
post.user_id, post.username, post.post_date,
bb_code_parse_cache.parse_tree AS message_parsed, bb_code_parse_cache.cache_version AS message_cache_version,
user.*, IF(user.username IS NULL, post.username, user.username) AS username,
user_profile.*,
user_privacy.*,
signature_parse_cache.parse_tree AS signature_parsed, bb_code_parse_cache.cache_version AS signature_cache_version,
session_activity.view_date AS last_view_date,
0 AS like_date
FROM xf_post AS post
INNER JOIN xf_thread AS thread ON
(thread.thread_id = post.thread_id)
LEFT JOIN xf_bb_code_parse_cache AS bb_code_parse_cache ON
(bb_code_parse_cache.content_type = 'post' AND bb_code_parse_cache.content_id = post.post_id)
LEFT JOIN xf_user AS user ON
(user.user_id = post.user_id)
LEFT JOIN xf_user_profile AS user_profile ON
(user_profile.user_id = post.user_id)
LEFT JOIN xf_user_privacy AS user_privacy ON
(user_privacy.user_id = post.user_id)
LEFT JOIN xf_bb_code_parse_cache AS signature_parse_cache ON
(signature_parse_cache.content_type = 'signature' AND signature_parse_cache.content_id = post.user_id)
LEFT JOIN xf_session_activity AS session_activity ON
(post.user_id > 0 AND session_activity.user_id = post.user_id AND session_activity.unique_key = CAST(post.user_id AS BINARY))
WHERE (
(post.thread_id = ? AND (post.position >= 0 AND post.position < 10) )
)
AND (post.message_state IN ('visible'))
ORDER BY post.position ASC, post.post_date ASCParams: 590716
Run Time: 0.002996
| Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
|---|
| SIMPLE | thread | const | PRIMARY | PRIMARY | 4 | const | 1 | Using filesort |
| SIMPLE | post | ref | thread_id_post_date,thread_id_position | thread_id_post_date | 4 | const | 1 | Using index condition; Using where |
| SIMPLE | bb_code_parse_cache | eq_ref | content_type_id | content_type_id | 31 | const,xenforo.cc.post.post_id | 1 | Using where |
| SIMPLE | user | eq_ref | PRIMARY | PRIMARY | 4 | xenforo.cc.post.user_id | 1 | |
| SIMPLE | user_profile | eq_ref | PRIMARY | PRIMARY | 4 | xenforo.cc.post.user_id | 1 | |
| SIMPLE | user_privacy | eq_ref | PRIMARY | PRIMARY | 4 | xenforo.cc.post.user_id | 1 | |
| SIMPLE | signature_parse_cache | eq_ref | content_type_id | content_type_id | 31 | const,xenforo.cc.post.user_id | 1 | Using where |
| SIMPLE | session_activity | eq_ref | PRIMARY | PRIMARY | 22 | xenforo.cc.post.user_id,func | 1 | Using where |
INSERT INTO xf_thread_view
(thread_id)
VALUES
(?)
Params: 590716
Run Time: 0.000086
INSERT INTO `xf_session` (`session_id`, `session_data`, `expiry_date`) VALUES (?, ?, ?)
Params: a07b8b3da2e5021cc7815335ac375c03, , 1714850581
Run Time: 0.000941
INSERT INTO xf_session_activity
(user_id, unique_key, ip, controller_name, controller_action, view_state, params, view_date, robot_key)
VALUES
(?, ?, ?, ?, ?, ?, ?, ?, ?)
ON DUPLICATE KEY UPDATE
ip = VALUES(ip),
controller_name = VALUES(controller_name),
controller_action = VALUES(controller_action),
view_state = VALUES(view_state),
params = VALUES(params),
view_date = VALUES(view_date),
robot_key = VALUES(robot_key)
Params: 0, , , XenForo_ControllerPublic_Thread, Index, valid, thread_id=590716, 1714846981,
Run Time: 0.000105
INSERT INTO xf_bb_code_parse_cache
(content_type, content_id, parse_tree, cache_version, cache_date)
VALUES (?, ?, ?, ?, ?)
ON DUPLICATE KEY UPDATE parse_tree = VALUES(parse_tree),
cache_version = VALUES(cache_version),
cache_date = VALUES(cache_date)
Params: post, 597872, a:19:{i:0;a:4:{s:3:"tag";s:1:"b";s:6:"option";N;s:8:"original";a:2:{i:0;s:3:"[B]";i:1;s:4:"[/B]";}s:8:"children";a:1:{i:0;s:233:"卡尔加里大学的一项研究发现，非专利药物羟氯喹在用于治疗原发进展型多发性硬化症（MS）的残疾演变时取得了可喜的成果，这是一种最不容易治疗的自身免疫性疾病的形式。";}}i:1;s:159:"多发性硬化症影响了约9万名加拿大人，其中约15%被诊断为原发进展型多发性硬化症，是世界上发病率最高的疾病之一。
";i:2;a:4:{s:3:"tag";s:6:"center";s:6:"option";N;s:8:"original";a:2:{i:0;s:8:"[CENTER]";i:1;s:9:"[/CENTER]";}s:8:"children";a:1:{i:0;a:4:{s:3:"tag";s:3:"url";s:6:"option";s:84:"https://n.sinaimg.cn/finance/transform/484/w310h174/20200405/ed0a-irtymmw4210753.png";s:8:"original";a:2:{i:0;s:92:"[URL='https://n.sinaimg.cn/finance/transform/484/w310h174/20200405/ed0a-irtymmw4210753.png']";i:1;s:6:"[/URL]";}s:8:"children";a:1:{i:0;a:4:{s:3:"tag";s:3:"img";s:6:"option";N;s:8:"original";a:2:{i:0;s:5:"[IMG]";i:1;s:6:"[/IMG]";}s:8:"children";a:1:{i:0;s:84:"https://n.sinaimg.cn/finance/transform/484/w310h174/20200405/ed0a-irtymmw4210753.png";}}}}}}i:3;s:2:"
";i:4;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:250:"由Marcus Koch博士和Wee Yong博士领导的Cumming医学院研究小组发现，在涉及卡尔加里多发性硬化症诊所参与者的18个月研究中，羟氯喹有助于减缓残疾的恶化。该研究发表在《神经病学年鉴》上。";}}i:5;s:2:"
";i:6;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:579:"“对于原发进展型多发性硬化症，没有好的治疗方法来阻止或逆转疾病的进展。残疾会随着时间的推移而逐渐恶化，”临床神经科学系的临床研究员和霍奇基斯-布莱恩研究所（HBI）的成员Koch说。“Yong博士的研究团队与我们密切合作，几年来一直在筛选大量的非专利药物，羟氯喹的结果显示出一些希望。我们的试验是一个初步的成功，需要进一步研究。我们希望分享这些结果将有助于激发这项工作，特别是未来更大规模的临床试验。”";}}i:7;s:2:"
";i:8;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:303:"这项实验研究被称为单臂II期无用性试验，在2016年11月至2021年6月期间对35人进行了跟踪。研究人员预计至少有40%，即14名参与者的行走功能会出现明显恶化，但在试验结束时，只有8名参与者出现了恶化。羟氯喹的耐受性普遍良好。";}}i:9;s:2:"
";i:10;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:228:"羟氯喹是一种抗疟疾药物，更常用于控制类风湿性关节炎和自身免疫性疾病（如红斑狼疮）的症状。之所以选择它，是因为它被广泛用于风湿病，而且一般来说耐受性良好。";}}i:11;s:3:"
";i:12;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:356:"“根据我们实验室对多发性硬化症模型的研究，我们预测羟氯喹将减少多发性硬化症患者的残疾。卡尔加里有一个充满活力的从实验室到床边的多发性硬化症项目，Koch博士的试验工作提供了进一步的证据，我们很高兴看到这一点，”临床神经科学系教授和HBI成员Yong说。";}}i:13;s:2:"
";i:14;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:285:"多发性硬化症的原因仍然不明。这是一种身体的免疫系统攻击自身组织的疾病，通常持续时间长，经常影响大脑、脊髓和眼睛里的视神经。它可以导致视力、平衡和肌肉控制方面的问题，尽管每个患者的影响都不同。";}}i:15;s:2:"
";i:16;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:256:"多发性硬化症临床试验团队的工作部分得到了包括Westman 慈善基金会和Swartout家族在内的捐赠者的慈善捐款支持。这项具体研究还得到了Hotchkiss脑科研究所多发性硬化症转化临床试验项目的资助。";}}i:17;s:2:"
";i:18;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:241:"Koch博士和研究团队几年来一直在研究羟氯喹对原发进展型多发性硬化症的影响，这项工作仍在继续，包括它作为一种治疗方法与选定的其他普通药物联合使用可能会取得更大的效果。";}}}, 1621686945, 1714846981
Run Time: 0.000835